


IMIDAZO[4,5-*e*][1,2,4]TRIAZOCINE: A NOVEL 5:8-FUSED RING SYSTEM RIDDLED WITH REARRANGEMENTS

Friedrick N. Burnett and Ramachandra S. Hosmane*

Laboratory for Drug Design and Synthesis
Department of Chemistry and Biochemistry
University of Maryland Baltimore County
Baltimore, Maryland 21228, USA

Abstract - Attempts to synthesize the title 5:8-fused heterocyclic ring system resulted in a number of novel opportunistic rearrangements and transformations. There is, however, some evidence to believe that one of these rearrangements might proceed through the transient intermediacy of this ring system.



- 1; R = R' = H
2; R = R' = CH₂Ph
3; R = CH₂Ph, R' = H
4; R = H, R' = CH₂Ph


Heterocycles with structural features that resemble ring-expanded purines are of chemical, biochemical, biophysical, as well as medicinal interest. In this regard, while several 5:7-fused heterocyclic ring-systems containing both imidazodi- and -triazepine nuclei have been extensively explored, both in this laboratory¹ and elsewhere,² as ring-expanded purine bases, nucleosides, and nucleotides, little is documented on the related 5:8-fused systems. Large ring heterocycles pose considerable synthetic challenge, especially when dealing with antiaromatic ring systems, which are often plagued with undesired, opportunistic rearrangements. We have indeed uncovered a few such rearrangements during the synthesis of heterocycles containing the 5:7-fused imidazo[4,5-*e*][1,2,4]triazepine ring skeleton,³

although most of the target compounds were later found to be remarkably stable when once synthesized. Reported herein are our synthetic endeavors on the larger 5:8-fused imidazo[4,5-*e*][1,2,4]triazocine ring system (1-4). As delineated, while there is some evidence for the existence of such a ring system as a transient intermediate, all our efforts thus far to isolate a representative member of this class of compounds have only led to products resulting from a variety of opportunistic, nonetheless interesting, rearrangements and transformations.

As an initial synthetic target, we chose 1--a ring-expanded analogue of xanthine--as it could later be conveniently converted into the corresponding adenine and guanine analogues. Our synthesis commenced with 1-benzyl-5-methyl-4-nitroimidazole (5)⁴ (Scheme I), which was treated with dimethylformamide

dimethyl acetal, catalyzed by trifluoroacetic acid, to form 1-benzyl-5-[β -(*N,N*-dimethylamino)ethylene]-4-nitroimidazole, mostly as a *trans* isomer (**6**, mp 148-149 °C, ^1H NMR, MS, Anal. $\text{C}_9\text{H}_{11}\text{N}_3\text{O}_2$)⁵ in 85% yield. The

Scheme 1




enamine (**6**) was converted to the corresponding enol-acetate (**7**) as a mixture of *cis* and *trans* isomers in a 1:1 ratio (mp *cis* 82-84 °C, *trans* 129-130 °C, ^1H NMR, MS, Anal. $\text{C}_9\text{H}_{11}\text{N}_3\text{O}_2$)⁵ in 70% yield by reaction with acetic anhydride/ ammonium acetate. When **7** was treated with an equivalent of hydrazine, the sole product isolated was the acetylhydrazone (**9**) (mp 168-169 °C, ^1H NMR, MS, Anal. $\text{C}_9\text{H}_{11}\text{N}_3\text{O}_2$)⁵. Apparently, **7** undergoes initial deacylation to form the intermediate aldehyde (**8**) and acetylhydrazine, which further react to form **9**. Based upon this result, the desired **10** (foam, ^1H NMR, IR, Anal. $\text{C}_9\text{H}_{11}\text{N}_3\text{O}_2$)⁵ was prepared from **7** in 94% yield by reaction with two equivalents or more of methyl-carbazate. It was later discovered that **10** could also be prepared directly from **6** and methyl carbazate in 95% yield, although our earlier attempts of enamine exchange reactions of **6** with a variety of simple primary amines had failed. The 5-methylene group of **10** was oxidized to the corresponding keto group of **11** (mp 161-162 °C, ^1H NMR, MS, Anal.

$\text{C}_9\text{H}_{11}\text{N}_3\text{O}_2$)⁵ by treatment with sodium hydride in the presence of molecular oxygen in 27% yield. The structure of **11** was confirmed by single-crystal X-ray diffraction analysis.⁶ The nitro group of **11** was reduced by hydrogenation over 10% Pd-C to obtain the amino compound (**12**) (mp 193.5-195 °C, ^1H NMR, MS, UV, Anal. $\text{C}_9\text{H}_{11}\text{N}_3\text{O}_2$)⁵ in 73% yield. Compound (**12**) is the required precursor for the final ring-closure to form the target ring system.

The attempted ring-closure of **12** to **3** with sodium methoxide/ methanol, followed by acid work-up, however, produced only the degradation product, 5-acetyl-4-amino-1-benzylimidazole (**13**) (88%, mp 161-163 °C, ^1H

NMR, IR, MS).⁵ A tentative mechanism (Scheme II) for the formation of **13** involves the initial generation of the anion (**14**) which undergoes ring-closure to the oxadiazinone (**15**), which upon acid work-up ring opens to form **16**. Facile ring-opening reactions of oxadiazinones with nucleophiles are well documented.⁷ Intermediate (**16**) readily loses carbon dioxide and nitrogen gases to yield **17**. Finally tautomerization of **17** produces **13**.

Scheme II




to form **16**. Facile ring-opening reactions of oxadiazinones with nucleophiles are well documented.⁷ Intermediate (**16**) readily loses carbon dioxide and nitrogen gases to yield **17**. Finally tautomerization of **17** produces **13**.

In order to avoid the above undesired ring-closure, the anion-forming α -NH of the side-chain carbazate moiety was protected by benzylation. The dibenzyl product (**18**) (mp 128-130 °C, ¹H NMR, IR, MS, Anal. C₂₁H₂₀N₅)⁵ (Scheme III) could be prepared either from **11** using benzyl bromide/sodium hydride (48% yield) or directly from **10** in a one-pot reaction using the same reagents plus oxygen gas (18%).


Catalytic hydrogenation of **18** at 30 psi provided the desired **19** (mp 176-177 °C, ¹H NMR, IR, Anal. C₂₁H₂₀N₅)⁵ in 62% yield. However, when the same reaction was carried out under low pressure of hydrogen (10-15 psi), the dimer (**20**) (mp 212-214 °C, ¹H NMR, IR, UV, MS, Anal.

Scheme III



production of the decarboxymethylated product **21** (93%). Apparently, methoxide, acting as a nucleophile, attacks the methyl carbazate carbonyl, forming dimethyl carbonate and **21**. The ring-closure of **19** to **2** was, therefore, attempted with a non-nucleophilic base, *i.e.*, sodium hydride in dimethyl sulfoxide at 50-60 °C. However, this reaction gave instead the 5:6-fused 1,7-dibenzylxanthine (**22**) (41%). The structure of **22** was confirmed by single-crystal X-ray diffraction analyses.⁶ As outlined in Scheme IV, the observed transformation of **19** to **22** might indeed proceed by way of the desired 5:8-fused heterocyclic system **2**.

Scheme IV



ACKNOWLEDGMENT

This research was supported by grants from the National Institutes of Health (#GM 49249 & CA 71079). The mass spectra were run at the MSU-NIH Mass Spectral Facility, supported by an NIH grant (#P41 RR00480).

REFERENCES AND NOTES

1. (a) A. Bhan and R. S. Hosmane, *Nucleosides Nucleotides*, 1995, **14**, 455. (b) A. Bhan and R. S. Hosmane, *Synth. Commun.*, 1995, **25**, 2723. (c) A. Bhan and R. S. Hosmane, *Tetrahedron Lett.*, 1994, **35**, 6831. (d) L. Wang, A. Bhan, R. S. Hosmane, and R. D. Guiles, *Nucleosides Nucleotides*, 1994, **13**, 2307. (e) A. Bhan and R. S. Hosmane, *J. Heterocycl. Chem.*, 1993, **30**, 1453. (f) A. Bhan and R. S. Hosmane, *Nucleosides Nucleotides*, 1992, **11**, 1175. (g) V. S. Bhadti, R. S. Hosmane, and M. Hulce, *Nucleosides Nucleotides*, 1992, **11**, 1137. (h) R. S. Hosmane, V. P. Vaidya, M. K. Chung, U. Siriwardane, H. M. Zhang, and N. S. Hosmane, *Nucleosides Nucleotides*, 1991, **10**, 1693. (i) R. S. Hosmane, A. Bhan, M. Hulce, H.M. Zhang, and N. S. Hosmane, *Nucleosides Nucleotides*, 1991, **10**, 819. (j) R. S. Hosmane, A. Bhan, R. L. Karpel, U. Siriwardane, and N. S. Hosmane, *J. Org. Chem.*, 1990, **55**, 5882. (k) R. S. Hosmane and A. Bhan, *Nucleosides Nucleotides*, 1990, **9**, 913. (l) R. S. Hosmane, V. S. Bhadti, and B. B. Lim, *Synthesis*, 1990, 1095. (m) R. S. Hosmane and A. Bhan, *J. Heterocycl. Chem.*, 1990, **27**, 2189. (n) R. S. Hosmane and A. Bhan, *Biochem. Biophys. Res. Commun.*, 1989, **165**, 106.
2. (a) J. W. Daly, I. Hide, and P. K. Bridson, *J. Med. Chem.*, 1990, **33**, 2818. (b) P. K. Bridson and T. P. Weirich, *J. Heterocycl. Chem.*, 1988, **25**, 1179. (c) P. K. Bridson and S. J. Lambert, *J. Chem. Soc., Perkin Trans. 1*, 1990, 173. (d) P. K. Bridson, H. A. Kurtz, and F. Sayyarpour, *J. Mol. Struct. (Theochem.)*, 1989, **199**, 175. (e) A. Edenhofer, *Helv. Chim. Acta*, 1975, **58**, 2192. (f) E. I. Ivanov, A. V. Bogatskii, and K. S. Zakharov, *Dokl. Akad. Nauk SSSR*, 1980, **255**, 591.
3. (a) R. S. Hosmane, B. B. Lim, and F. N. Burnett, *J. Org. Chem.*, 1988, **53**, 382. (b) R. S. Hosmane, B. B. Lim, M. F. Summers, U. Siriwardane, N. S. Hosmane, and S. C. Chu, *J. Org. Chem.*, 1988, **53**, 5309. (c) R. S. Hosmane and B. B. Lim, *Heterocycles*, 1988, **27**, 31. (d) R. S. Hosmane and B. B. Lim, *Synthesis*, 1988, 242. (e) C. Afshar, H. M. Berman, P. Sawzik, L. Lessinger, B. B. Lim, and R. S. Hosmane, *J. Cryst. Spec. Res.*, 1987, **17**, 533.
4. R. S. Hosmane, A. Bhan, and M. E. Rauser, *J. Org. Chem.*, 1985, **50**, 5892.
5. The elemental microanalyses, performed by Atlantic Microlab, Inc., were within 0.4% of the calculated values. The spectral data are consistent with the structure assigned.
6. The X-ray diffraction analyses were performed by Dr. Hongming Zhang at the Department of Chemistry, Southern Methodist University, Dallas, Texas.
7. R. Gomper and F. Towae, *Synthesis*, 1975, 522.

Received, 28th February, 1997